ReviewIranian journal of public health2015
The CD4+/CD8+ Ratio in Pulmonary Tuberculosis: Systematic and Meta-Analysis Article.
Review in Iranian journal of public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Clinical effect of spleen aminopeptide on improving liver function damage and immune function in children with infant hepatitis syndrome.World journal of gastrointestinal surgery · 2024Trial
- A mouse model to study persistent fatigue.Research square · 2026Article
- Immunomodulatory Effects ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Case Report: Sarcoidosis or tuberculosis? A continuous challenge.Frontiers in medicine · 2025Article
- Predictive value of procalcitonin for the therapeutic response of patients with uroseptic shock: a retrospective case-control study.American journal of translational research · 2025Article
- Diagnosis of pulmonary sarcoidosis in tuberculosis endemic area-a narrative review.Journal of thoracic disease · 2023Review
- Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Clinical characteristics and risk factors predictive of pulmonary embolism complicated in bronchiectasis patients: a retrospective study.BMC pulmonary medicine · 2022Article
- Opinion Polls and Antibody Response Dynamics of Vaccination with COVID-19 Booster Vaccines.Vaccines · 2022Article
- Prevalence of anaemia and associated factors among people with pulmonary tuberculosis in Uganda.Epidemiology and infection · 2022Article
- Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma.Cancer management and research · 2022Article
- Prevalence and Predictors of CD4+ T-Lymphocytopenia Among HIV-Negative Tuberculosis Patients in Uganda.Research and reports in tropical medicine · 2020Article
- Prevalence of Malaria and TB Coinfection at a National Tuberculosis Treatment Centre in Uganda.Journal of tropical medicine · 2019Article
- Protective effects and immunomodulation on piglets infected with rotavirus following resveratrol supplementation.PloS one · 2018Article
- The effects of anti-Fas ribozyme on T lymphocyte apoptosis in mice model with chronic obstructive pulmonary disease.Iranian journal of basic medical sciences · 2017Article
- Vitamin D improves immune function in immunosuppressant mice induced by glucocorticoid.Biomedical reports · 2017Article
- Bronchoalveolar Lavage Fluid Characteristics of Patients With Sarcoidosis and Nonsarcoidosis Interstitial Lung Diseases: Ten-Year Experience of a Single Center in Turkey.Iranian Red Crescent medical journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ratio of CD4+/CD8+ has been used as a clinically index to evaluate patients' immunity. Numerous researchers have studied CD4+/CD8+ ratio in pulmonary tuberculosis (PTB) patients. However, the change of CD4+/CD8+ ratio remains controversial. We present a meta-analysis of 15 case-control studies to identify the change of CD4+/CD8+ ratio in PTB patients.
methodsWe assessed heterogeneity of effect estimates within each group using I(2) test. Subgroup analysis was performed to explore the potential source of heterogeneity. To investigate further the potential publication bias, we visually examined the funnel plots. For robustness of results, we performed sensitivity analysis by removing studies. Data entry and analyses were carried out with RevMan 5.2 (The Nordic Cochrane Centre).
resultsTwelve peripheral blood studies were categorized into two subgroups. Eight studies presented a significant decrease of CD4+/CD8+ ratio in PTB cases compared to healthy subjects (SMD: -0.45; 95% CI -0.65--0.25; I(2) = 7%). Other four studies researched on the newly diagnosed patients presented a more seriously and significantly decrease (SMD: -2.17; 95% CI -2.61--1.74; I(2) = 37%). The pooled analysis of bronchoalveolar lavage fluid (BALF) studies showed a significant increase of CD4+/CD8+ ratio using Flow Cytometry (FCM) (SMD: 4.75; 95% CI 3.44-6.05; I(2) =0%).
conclusionThe present meta-analysis indicated that there was a synthetic evidence for the reduced CD4+/CD8+ ratio in peripheral blood of PTB patients, especially newly diagnosed cases. However, the CD4+/CD8+ ratio in BALF was increased using method of FCM.
Indexed as
Identifiers
25905052PMC4401876W2152231701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.